Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

JOURNAL ARTICLE

Nonhistaminergic idiopathic angioedema: clinical response to icatibant

C Colás, R Montoiro, J Fraj, M Garcés, J L Cubero, T Caballero

Journal of Investigational Allergology & Clinical Immunology 2012, 22 (7): 520-1

No abstract text is available yet for this article.

Full Text Links

Find Full Text Links for this Article

You are not logged in. Sign Up or Log In to join the discussion.

Treatment of idiopathic nonhistaminergic angioedema with bradykinin B2 receptor antagonist icatibant. I Del Corso, I Puxeddu, E Sardano, S Geraci, M Breggia, V Rocchi, P Migliorini Annals of Allergy, Asthma & Immunology 2012, 108 (6): 460-1

Successful treatment of a facial attack of angioedema with icatibant in a patient with idiopathic angioedema. Vincenzo Montinaro, Giuliana Loizzo, Anna Zito, Giuseppe Castellano, Loreto Gesualdo American Journal of Emergency Medicine 2013, 31 (8): 1295.e5-6

Nonhistaminergic idiopathic angioedema may be a presentation of mast cell activation syndrome. L B Afrin Journal of Investigational Allergology & Clinical Immunology 2013, 23 (3): 212

Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Murat Bas, Jens Greve, Klaus Stelter, Henning Bier, Thomas Stark, Thomas K Hoffmann, Georg Kojda Annals of Emergency Medicine 2010, 56 (3): 278-82

Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. Delphine Charignon, Peter Späth, Ludovic Martin, Christian Drouet Expert Opinion on Pharmacotherapy 2012, 13 (15): 2233-47

Management of acute attacks of hereditary angioedema: potential role of icatibant. Hilary J Longhurst Vascular Health and Risk Management 2010, 6: 795-802

Make the most of Read.
Download the mobile app.

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Read